The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease

Craig W Ritchie,[1,2] Karen Ritchie[3,4,5]

ABSTRACT

Introduction: Epidemiological studies indicate that significant decreases in the incidence of Alzheimer's disease (AD) may be obtained by targeting multiple middle-age risk factors. However, as dementia is unlikely to be diagnosed for decades, short-term outcome measures are required. AD biomarker changes precede clinical symptoms by many years, but their sensitivity to mid-life change remains unknown.

Methods and analysis: PREVENT is a prospective cohort study examining biomarker status at mid-life in at least 150 individuals genetically at high, medium or low risk of late-onset AD. Participants are children of individuals with or without a diagnosed AD allocated to high, medium and low-risk groups according to parental clinical status and ApoE genotype. The biomarkers examined over 2 years are plasma and CSF Aβ42 amyloid, Tau and pTau, proinflammatory cytokines, acute-phase proteins, medial temporal-lobe atrophy, white matter lesion volume, cognitive performance related to transentorhinal and hippocampal functioning and hypothalamic−pituitary−adrenal and sympathetic axes regulation.

Ethics and dissemination: Detected pathologies are communicated to the participant's general practitioner with their permission. Risk status by genotype would not be revealed. The results of the study would be published in peer-reviewed journals and validated biomarkers used to construct a randomised controlled intervention study.

[1]Centre for Mental Health, Imperial College London, London, UK
[2]West London Mental Health Trust, London, UK
[3]Neuroepidemiology of Ageing Research Unit, Imperial College, London, UK
[4]U1061 Neuropsychiatry, Inserm, Montpellier, France
[5]Université de Montpellier 1, Montpellier, France

Correspondence to
Dr Karen Ritchie;
karen.ritchie@inserm.fr

INTRODUCTION

In the face of a pandemic of dementia with predicted increases of 100% in developed countries between 2001 and 2020,[1] even small reductions in the incidence, or delaying the age of the onset, are likely to have significant effects with regard to the enormous associated public health burden. The exact cause of the dementia remains unknown, however, epidemiological studies conducted over the past decade together suggest a complex interaction of exposures which contribute differentially to the probability and timing of the disease onset and could be used as the basis for strategies to reduce risk and delay onset in the absence of specific disease-modifying treatments. While no single risk factor explains a sufficient variance to be used individually as a basis for prevention, simulation studies in analytical epidemiology show that highly significant decreases in population incidence might be obtained by targeting simultaneously multiple high-risk factors.[2][3] Exposure to many of these risk factors occurs in middle age, for example, hypertension and diabetes, suggesting that maximal impact is likely to be obtained by targeting middle-age populations with a high risk of a later-life dementia. The pivotal question, however, is what to measure as an outcome indicator at this early stage given that clinical dementia is unlikely to be diagnosed for another 20−40 years.

Recent research on cognitive, neuroimaging and biological markers suggest that changes in several parameters may well precede overt clinical symptoms by not just many years, but decades. Only one study to our knowledge has attempted to examine a biomarker at this very early stage; Alexopoulos *et al*[4] have shown that young (mean age 24), healthy ApoE ε4 carriers have statistically significantly smaller hippocampal volumes than ApoE ε2 carriers. This observation is in support of our assumption, however, it requires confirmation in another data set and hippocampal size alone is an insufficient evidence of early AD vulnerability. The aim of the PREVENT study is to examine the sensitivity of a wide range of candidate markers in mid-life to provide measures for future interventional research.

METHODS
Selection of candidate biomarkers
Amyloid

There is increasing evidence that Aβ deposition in plaques precedes any sign of dementia by years, if not decades.[5][6] Though more accessible, plasma Aβ has given inconclusive results in terms of its predictive value[7] when compared to PIB PET,[8] while the predictive value of cerebrospinal fluid (CSF) $A\beta_{42}$ appears to directly reflect early brain deposition.[9][10] $A\beta_{42}$ paradoxically decreases in CSF with an increasing deposition, hypothesised to be due to plaques acting as an $A\beta_{42}$ 'sink' preventing the transport of soluble $A\beta_{42}$ to the CSF.[11] In the progression of pathology, plaque formation and the associated capture of the central Aβ into the plaque with consequential lowering of CSF Aβ is considered a primary event that precedes the hyperphosphorylation of tau and neuronal disintegration. $A\beta_{42}$ has thus been recommended for use as an endpoint for future preventive programmes in younger adults[9] and has also been incorporated into the revised diagnostic criteria for preclinical dementia.[12] Alternatively amyloid may be intracerebrally observed and quantified through functional imaging of a radio-labelled Aβ ligand, however this method is far more expensive and less widely applicable.[8][10][13]

Tau

Like $A\beta_{42}$, tau and phosphorylated tau have emerged as important CSF biomarkers for preclinical Alzheimer's disease (AD). Increased concentrations of tau and phosphorylated tau correlate with both neuritic-plaque density and Braak NFT stage. In conjunction with $A\beta_{42}$, tau and phosphorylated tau seem to be useful as prognostic biomarkers for conversion not only from cognitive impairment to dementia, but also from cognitively normal to mild cognitive impairment.[8][10][13–15] As an indicator of neuronal death CSF tau is elevated in all types of neurodegenerative diseases as well as post stroke. As the hyperphosphorylation of Tau is believed to be relatively specific to AD, the observation of elevated CSF pTau is thought to be a more specific early indicator of neurodegeneration secondary to AD. The combination of high tau and low Ab42 as a ratio is considered to have an even greater accuracy for identifying AD.[16]

Inflammation

The occurrence of plaque-dependant inflammation in AD has been consistently observed in both humans and transgenic models[17][18] with animal studies suggesting that a pro-inflammatory process may even be initiated before plaque deposition[17][18] making it potentially the earliest preclinical indicator. Imaging studies provide further support for this hypothesis with observations of microglia activation before plaque formation. Further support comes from epidemiological observations of cognitive decline due to systemic infections and perioperatively where elevation of systemic inflammatory proteins such as cytokines and interleukins may mediate a reactive activation of glial cells and consequent acceleration of oligomerisation.[19] Taken together, it would appear that inflammatory markers may elevate prior to a lowering of CSF Aβ (as a marker of Aβ oligomerisation) which in turn precedes the elevation of tau (as a marker of neurodegeneration). The sequence of events is still, however, poorly understood although vital to the development of prevention programmes as it is likely to be a dynamic indicator differing according to distance from the dementia onset at the time of CSF sampling.

Structural brain imaging

Atrophy is particularly difficult to measure in the preclinical stages of dementia, when it superficially resembles the inconspicuous volume loss commonly observed among ageing individuals without neurodegeneration. Distinguishing such subtle differences is now possible using high-resolution quantitative MRI[20] which is able to predict not only a progression from mild cognitive impairment to AD,[21] but also from normal cognition to mild cognitive changes.[22] Numerous cross-sectional and longitudinal MRI studies have now been conducted to identify markers which may indicate presymptomatic dementia. The focus of these studies has been on medial temporal atrophy, with the hippocampus and entorhinal cortex being affected before symptoms emerge.[23][24] It has been estimated that subjects with cognitive difficulties in the years before dementia diagnosis already show hippocampal loss of 7–15%[25] and entorhinal cortical loss of 5–32%.[26] Although atrophy is often thought to be a downstream marker from amyloid in the cascade leading to dementia,[27] it appears to represent both neuronal loss and the presence of tau pathology, so may be directly related to the AD pathophysiological process.[28] Both hippocampal volume loss and white-matter lesions are seen in other disorders which are significant up-stream risk factors for dementia, such as depression.[29]

Cognition

While cognitive dysfunction is generally considered to occur closer to the time of AD clinical manifestation, this is probably largely due to the nature of the cognitive tests which have been used, which have been principally derived from comparisons of AD and normal subjects. Sing-Manoux et al[30] have recently observed a cognitive decline in adults aged 45–49 years in a large prospective cohort study; however, while the authors suggest that this group may be at a high risk of later dementia, no association was sought either with other dementia-related risk factors or later-life biomarkers. Dizygotic twin studies in which only one twin developed AD have shown on the other hand that significant differences in cognitive performance may be evidenced up to 20 years before AD diagnosis.[31] While there is currently very little evidence as to which tests may be sensitive decades before diagnosis, histopathological studies point to the transentorhinal cortex as the first anatomical target

followed by the entorhinal cortex and hippocampus. Evidence from lesion studies in humans and experimental animals[32] [33] and functional neuroimaging in normal adults[34] suggest on this basis that a decline in visuospatial associative learning to be a primary candidate for a very early marker. Longitudinal studies of prodromal dementia accompanied by a blind assessment of MRI imaging suggests that diffuse cerebral and mediotemporal-lobe atrophy in preclinical cases may also be evidenced by a lower verbal memory and visuospatial analyses tasks before evidence on brain imaging.[35] While verbal learning tasks are often included in a dementia assessment, the more complex processes of visuospatial information processing have till date been inadequately explored in preclinical studies.

Hypothalamic−pituitary−adrenal axis functioning

Physiological mediators such as glucocorticoids (hypothalamic−pituitary−adrenal, HPA, axis) from the adrenal cortex and adrenalin (sympathetic axis) from the adrenal medulla act upon receptors in various tissues and organs to produce effects that are damaging if continuously activated.[36] In response to stressful conditions, chronic overactivity and dysregulation of these stress systems can thus play a pivotal role in critical biological processes, such as growth, intermediary metabolism and diabetes, immune and inflammatory reactions as well as (cardio)vascular and central nervous system functions. Glucocorticoids generally work in opposition to insulin, except under a state of chronic glucocorticoid elevation, in which case they act to promote hepatic glycogen deposition and lipogenesis that leads to fat deposition, while raising insulin levels and impairing insulin actions on their receptors. It has been demonstrated[37] that whereas cardiovascular risk factors, type 2 diabetes and stroke form anthropometric, metabolic and haemodynamic clusters in correlation analyses in the general population, most of these risk factors also seem to form one tightly assembled cluster in individuals with HPA axis dysregulation suggesting this could be an overriding factor for the established risk factors targeted in this study and may thus constitute a very early biomarker of an increased risk for cognitive decline. Disturbance on cortisol secretion has been reported in cognitive impairment and AD.[38–41] In a mouse model of AD, glucocorticoid increased Aβ and tau pathology, but an inverse weak association was found in a small clinical study of AD patients.[42] [43] Increase in cortisol levels and in mineralocorticoid receptor expression in the frontal cortex has been reported in AD and this correlated negatively to global cognitive function and positively to frontal cortex amyloid-β levels in Apo E4 carriers.[44] Higher cortisol levels have been associated with hippocampal atrophy. In healthy men, significant negative phenotypic associations were found between cortisol levels and the thickness of left dorsolateral and ventrolateral prefrontal regions, and right dorsolateral and medial orbital frontex.[45] Recent fMRI studies suggest a

dynamically changing corticosteroid effects with reduced prefrontal and hippocampal responses as well as an altered coupling of the amygdala with the medial prefrontal cortex.[46] [47] Thus, while there is some evidence to suggest a major role of the stress system in the early onset of dementia, this hypothesis has yet to be tested. A number of previous studies being cross-sectional, focusing on elderly and cortisol secretion with a limited number of measurements and limited neuropsychological evaluation were indeed inconclusive regarding the early temporal relation between the whole functioning of stress axes and dementia.

The specific hypotheses being examined within the PREVENT Project are:

1. That at mid-life (40−59 years), individuals at a high risk of dementia show significant decreases in Aβ42 amyloid in plasma and CSF and increases in Tau and pTau (and their ratios) as compared to that in low-risk individuals.
2. High-risk individuals show increased mid-life activity on pro-inflammatory cytokines IL-1α, IL1β, IL-18, IL-6, IL-8, TNF-α, IFN-γ, acute phase proteins (CRP, haptoglobin, sialic acid pr) and a long-term inflammatory marker (orosomucoid).
3. High-risk individuals at mid-life have increased medial temporal lobe atrophy and white matter lesion volume. The MRI protocol includes entire brain volumetric T1 weighted images (1×1×1 mm) for segmentation and volumetric analyses, dual echo and FLAIR sequences to allow identification and quantification of deep white matter hyperintensities and diffusion-weighted imaging (minimum 16 directions) for identification of changes in normal appearing white matter and major tracts.
4. High-risk individuals have poorer performance (both accuracy and information processing time) in cognitive tasks reflecting transentorhinal and entorhinal cortical changes and hippocampal reduction as evidenced notably by visuospatial associative learning, spatial analysis and working and primary memory tasks.
5. High-risk individuals show evidence at mid-life of HPA and sympathetic axes dysregulation as evidenced by secretion of cortisol and catecholamines, for example, epinephrine, norepinephrine, dopamine and metabolites of degradation (metanephrine, nor-metanephrine).
6. Differences in biomarker levels and cognitive performance will be evidenced on both cross-sectional and longitudinal (over 2 years) measures.

Participants

Participants are the children of individuals diagnosed with AD at the West London Mental Health Trust (WLMHT) Cognitive Disorders and Dementia clinics who have given consent to the study and for whom we have obtained information on genetic risk (ApoE status). Participants are drawn from the locally hosted Dementia Register (DemReg),[48] which holds details on both patients with dementia and their cares (40% of whom are children).

Fifty children of the patients diagnosed with AD and an ApoE ε4 allele (high risk), 50 children of demented patients without an ApoE ε4 allele (medium risk) and 50 participants without a parent with dementia (eg, spouses of extant cases on the register) and with an ApoE ε2 and no ApoE ε4 allele (low risk) will be followed up for over 2 years. A medium-risk group is included to detect a possible 'dose' effect and to maintain study blinding, this group will probably number in excess of 50 participants. Power calculations are difficult to make in this context given that SDs on the biomarkers in this younger age group are as-yet unknown, apart from the hippocampal volume study of Alexopoulos *et al*[4] cited hereinbefore. Data from this study were normally distributed, the APOE ε2 group having a hippocampal volume mean (SD) of 4.59 cc (0.50 cc). On this basis, 50 subjects per group would allow us to show a mean difference of 0.327 between the groups; that is, a mean of 4.263 in the APOE ε4 group with an α risk=0.05 and a power of 0.90. Examining data from a very large longitudinal population study of over 10 000 people aged 65 and over (the 3 City Study, Montpellier), we observed the plasma biomarker Aβ42 to have the largest SD likely to diminish power. Based on the data from this study we therefore made a supplementary 'worst-case scenario' calculation. The mean (SD) level of plasmatic Aβ42 in this study is 38.90 (12.326), and on this basis 50 subjects in each of our groups would permit us to show a mean difference of 8.07 with an α risk=0.05 and 0.90 power. This is clearly poorer, but we are unlikely to see levels this low in the PROGENY cohort with CSF rather than plasmatic Aβ.

Procedures

Potentially eligible individuals will be sent a Participant Information Sheet by post. All participants in the study are seen at the West London Cognitive Disorders Treatment and Research Unit in West London Mental Health Trust, West London. The other principal interest of this clinical service is that its catchment area is principally of Asian Indian origin, with very high rates of AD risk factors (diabetes, hypertension and stroke). On attendance, one of the study clinicians would present the project and take informed consent. Separate consents would be taken for CSF sampling so that participants may still be part of the PREVENT cohort for subsequent studies if they refused the CSF extraction, however, only subjects accepting this procedure would be included in this first biomarker validation study. Consented participants would then be interviewed by the study team who complete a standardised neuropsychiatric interview and a life-style questionnaire covering diet, occupation, work, education, life-time activity, adverse environmental exposures, alcohol and drug use. A battery of neuropsychometric tests focusing particularly on entorhinal and hippocampal functioning (the COGNITO battery) is administered using a tactile screen to permit recording of response latencies and qualitative aspects of performance (the manual for this test may be viewed on the following site: http://www.montp.inserm.fr/u1061/SiteU1061/PDF/COGNITO%20MANUAL%20ENGLISH.pdf).

Our group has also developed a visual short-term memory binding paradigm that has been shown to predict familial AD 10–15 years before appearance of clinical symptoms in the absence of detectable changes in other neuropsychological tests[49] which would be applied as a supplementary cognitive test.

Upon completion, a blood sample would be taken and a physical examination conducted including anthropometry and pulse/BP. Saliva samples would be collected 4 times on the day of the clinical visit and participants would be asked to be prepared for a further four on a quiet day at home. Arrangements would also be made for CSF sampling and MRI. All procedures would be repeated at 24 months.

ApoE genotyping would be performed immediately after consent has been given permitting the research study manager to allocate subjects to high-risk, medium-risk and low-risk groups. Group allocation is known only to the manager, all other members of the research and clinical teams including the principal investigators being blind to group membership until all examinations have been conducted both at recruitment and follow-up.

ETHICS AND DISSEMINATION OF THE RESULTS

The principal ethical considerations relate to revelation of high AD risk status to participants and procedures to follow where pathology is detected. Following a discussion with the London Ethics Committee, it has been decided that as the risk status of potential participants is already known to them in that they have a parent with AD, it is not possible for them to be ignorant of their risk group, however, they would also be informed that this only places them at a higher risk and does not necessarily mean they will develop the disorder in their life-time. Results from genetic testing would not, however, be transmitted as this is neither an inevitable nor a treatable risk factor. Where pathologies are detected, the participant would be informed and permission requested to forward the relevant information to the individual's general practitioner.

Results from the PREVENT study would be published in peer-reviewed journals. Should valid biomarkers be found, after the 150 participants are entered, recruitment would continue for participation in future intervention studies as well as to provide greater analytical power for both baseline and longitudinal analyses.

Analyses

The preclinical biomarkers of AD would be compared between the three groups of subjects using analysis of variance for continuous variables with an approximately normal distribution or using the Kruskal-Wallis non parametric test for non normal continuous variables. The other characteristics of the subjects would also be compared between the three groups using the ANOVA or the Kruskal-Wallis tests for continuous variables and the χ^2 test

for categorical variables. In case of differences on socio-economic variables or other confounding variables between the three groups adjusted group comparisons would be undertaken using polytomous logistic regression.

CONCLUSIONS

The PREVENT Project would provide information on mid-life biomarker change in individuals at a high risk of late-onset AD. Should significant differences be found on any of the candidate measures, these biomarkers would then constitute endpoints for the construction of a large population randomised controlled trial based on intervention strategies already identified by our research teams. The results of the present study are also crucial to the development of other pharmaceutical and non-pharmaceutical interventions targeting early interventions in individuals at a risk of AD, and as such this study constitutes an important step forward for future prevention.

REFERENCES

1. Ferri C, Prince M, Brayne C, *et al.* Global prevalence of dementia: a Delphi consensus study. *Lancet* 2005;17:2112–9.
2. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol* 10:819–28.
3. Ritchie K, Carriere I, Ritchie CW, *et al.* Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. *BMJ* 341:c3885.
4. Alexopoulos P, Richter-Schmidinger T, Horn M, *et al.* Hippocampal volume differences between healthy young apolipoprotein E epsilon2 and epsilon4 carriers. *J Alzheimers Dis* 26:207–10.
5. Hulette CM, Welsh-Bohmer KA, Murray MG, *et al.* Neuropathological and neuropsychological changes in 'normal' aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. *J Neuropathol Exp Neurol* 1998;57:1168–74.
6. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. *J Mol Neurosci* 2001;17:101–18.
7. Song F, Poljak A, Valenzuela M, *et al.* Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease. *J Alzheimers Dis* 26:365–75.
8. Fagan AM, Mintun MA, Mach RH, *et al.* Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann Neurol* 2006;59:512–19.
9. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. *Arch Neurol* 2005;62:192–5.
10. Shaw LM, Vanderstichele H, Knapik-Czajka M, *et al.* Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann Neurol* 2009;65:403–13.
11. Fagan AM, Roe CM, Xiong C, *et al.* Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. *Arch Neurol* 2007;64:343–9.
12. Sperling RA, Aisen PS, Beckett LA, *et al.* Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7:280–92.
13. Jack CR Jr, Lowe VJ, Senjem ML, *et al.* 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. *Brain* 2008;131:665–80.
14. Hansson O, Zetterberg H, Buchhave P, *et al.* Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurol* 2006;5:228–34.
15. Li G, Sokal I, Quinn JF, *et al.* CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. *Neurology* 2007;69:631–9.
16. Petersen RC, Aisen PS, Beckett LA, *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology* 74:201–9.
17. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? *Curr Alzheimer Res* 8:164–74.
18. Strang F, Scheichl A, Chen YC, *et al.* Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer's disease? *Brain Pathol* 22:337–46.
19. Abildstrom H, Rasmussen LS, Rentowl P, *et al.* Cognitive dysfunction 1–2 years after non-cardiac surgery in the elderly. ISPOCD group. International study of post-operative cognitive dysfunction. *Acta Anaesthesiol Scand* 2000;44:1246–51.
20. Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. *Lancet* 1999;353:2125.
21. Devanand DP, Pradhaban G, Liu X, *et al.* Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. *Neurology* 2007;68:828–36.
22. Carlson NE, Moore MM, Dame A, *et al.* Trajectories of brain loss in aging and the development of cognitive impairment. *Neurology* 2008;70:828–33.
23. Killiany RJ, Hyman BT, Gomez-Isla T, *et al.* MRI measures of entorhinal cortex vs hippocampus in preclinical AD. *Neurology* 2002;58:1188–96.
24. Scahill RI, Schott JM, Stevens JM, *et al.* Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. *Proc Natl Acad Sci USA* 2002;99:4703–7.
25. Schott JM, Fox NC, Frost C, *et al.* Assessing the onset of structural change in familial Alzheimer's disease. *Ann Neurol* 2003;53:181–8.
26. Kantarci K, Jack CR Jr. Neuroimaging in Alzheimer disease: an evidence-based review. *Neuroimaging Clin N Am* 2003;13:197–209.
27. McKhann GM, Knopman DS, Chertkow H, *et al.* The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7:263–9.
28. Burton EJ, Barber R, Mukaetova-Ladinska EB, *et al.* Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. *Brain* 2009;132:195–203.
29. O'Brien JT, Lloyd A, McKeith I, *et al.* A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. *Am J Psychiatry* 2004;161:2081–90.
30. Singh-Manoux A, Kivimaki M, Glymour MM, *et al.* Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. *BMJ* 344:d7622.
31. LaRue A, Jarvik L. Cognitive function and prediction of dementia in old age. *Int J Ageing Hum Dev* 1987;25:79–89.
32. McDonald RJ, White NM. A triple dissociation of memory systems: hippocampus, amygdala, and dorsal striatum. *Behav Neurosci* 1993;107:3–22.
33. Smith ML, Milner B. The role of the right hippocampus in the recall of spatial location. *Neuropsychologia* 1981;19:781–93.
34. Maguire EA, Frith CD, Burgess N, *et al.* Knowing where things are parahippocampal involvement in encoding object locations in virtual large-scale space. *J Cogn Neurosci* 1998;10:61–76.
35. Laakso MP, Hallikainen M, Hanninen T, *et al.* Diagnosis of Alzheimer's disease: MRI of the hippocampus vs delayed recall. *Neuropsychologia* 2000;38:579–84.

36. Chrousos GP. Stress and disorders of the stress system. *Nat Rev Endocrinol* 2009;5:374–81.
37. Rosmond R, Bjorntorp P. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. *J Intern Med* 2000;247:188–97.
38. Beluche I, Chaudieu I, Norton J, *et al*. Persistence of abnormal cortisol levels in elderly persons after recovery from major depression. *J Psychiatr Res* 2009;43:777–83.
39. Csernansky JG, Dong H, Fagan AM, *et al*. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. *Am J Psychiatry* 2006;163:2164–9.
40. Franz CE, O'Brien RC, Hauger RL, *et al*. Cross-sectional and 35-year longitudinal assessment of salivary cortisol and cognitive functioning: the Vietnam Era twin study of aging. *Psychoneuroendocrinology* 36:1040–52.
41. Sousa N, Cerqueira JJ, Almeida OF. Corticosteroid receptors and neuroplasticity. *Brain Res Rev* 2008;57:561–70.
42. Green KN, Billings LM, Roozendaal B, *et al*. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. *J Neurosci* 2006;26:9047–56.
43. Laske C, Stransky E, Fritsche A, *et al*. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1–42 ratios in CSF in patients with mild Alzheimer's disease dementia. *Eur Arch Psychiatry Clin Neurosci* 2009;259:80–5.
44. Gil-Bea FJ, Aisa B, Solomon A, *et al*. HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer's disease. *J Alzheimers Dis* 22:829–38.
45. Kremen WS, O'Brien RC, Panizzon MS, *et al*. Salivary cortisol and prefrontal cortical thickness in middle-aged men: A twin study. *Neuroimage* 53:1093–102.
46. Henckens MJ, Pu Z, Hermans EJ, *et al*. Dynamically changing effects of corticosteroids on human hippocampal and prefrontal processing. *Hum Brain Mapp*.
47. Henckens MJ, van Wingen GA, Joels M, *et al*. Time-dependent effects of corticosteroids on human amygdala processing. *J Neurosci* 30:12725–32.
48. Iliffe S, Curry L, Kharicha K, *et al*. Developing a dementia research registry: a descriptive case study from North Thames DeNDRoN and the EVIDEM programme. *BMC Med Res Methodol* 11:9.
49. Parra MA, Abrahams S, Fabi K, *et al*. Short-term memory binding deficits in Alzheimer's disease. *Brain* 2009;132:1057–66.